Intratumorally administered oncolytic VACV (mJX-594, a murine variant of JX-594, Pexa-vec) potently increased CD8+ T cell proliferation, including of cancer antigen-specific CD8+ T cells, and decreased immunosuppressive cells irrespective of tissue type or therapeutic efficacy. Here, CD8A is linked to cancer.